[1] 姜德福, 程光惠, 马颖哲. 肿瘤细胞标志物与乳腺癌预后的相关性研究 [J]. 中华放射医学与防护杂志 2004.doi:10.3760/cma.j.issn.0254-5098.2004.04.026
[2] 杨小玲, 余伟江, 夏和顺. 影响乳腺癌预后的临床病理及生物学因素研究进展 [J]. 肿瘤防治研究 2004.doi:10.3971/j.issn.1000-8578.2004.01.023
[3] 陈勇, 赵充, 谢方云, 崔念基, 高剑铭. 410例乳腺癌生存因素分析 [J]. 中国肿瘤临床 2000.doi:10.3969/j.issn.1000-8179.2000.10.012
[4] 蒋明东, 李少林. 乳腺癌相关基因表达与乳腺癌预后评价 [J]. 细胞与分子免疫学杂志 2005.doi:10.3321/j.issn:1007-8738.2005.z1.036
[5] 张勇, 杨学伟. 乳腺癌nm23基因和雌、孕激素受体表达及其临床意义 [J]. 肿瘤学杂志 2004.doi:10.3969/j.issn.1671-170X.2004.06.011
[6] Grey S R, Dlay S S, Leone B E. Prediction of nodal spread of breast cancer by using artificial neural networkbased analyses of S100A4, nm23 and steroid receptor expression [J]. Clinical and Experimental Metastasis 2003, 20(06).
[7] Lee WY, Su WC, Lin PW, Guo HR, Chang TW, Chen HH. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. [J]. Oncology: International Journal of Cancer Research and Treatment 2004, 6(6).
[8] Cicenas J, Urban P, Vuaroqueaux V. Increased level of phosphorylated akt measured by chemiluminescencelinked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing c-erbB-2 [J]. Breast Cancer Research 2005, 7(03).
[9] Bottini A, Bermti A, BerSsiga A. p53 but not bcl-2 immunostaining is predictive of poorclinical complete respouse to primary chemotherapy in beast cancer patients [J]. Clinical Cancer Research 2006, 12(07).
[10] Yamashita H, Nishio M, Toyama T. Coexistence of HER2 over expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer [J]. Breast Cancer Research 2004, 6(01).
[11] Rudland P S, Platt H A, Renshaw C. Prgnostic siginificance of the metastasis-inducing protein S100A4 (p9Ka)in human breast cancer [J]. Cancer Research 2000, 60(15).
[12] Steeg P S, Bevilacqua G, Kopper L. Evidence for a novel gene associated with low tumor metastatic potential [J]. Journal of the National Cancer Institute 1998, 80(03). |
